DaVita (DVA) just posted third quarter results that showed higher revenue and earnings, alongside a lift in full year guidance. This puts the focus squarely on its Integrated Kidney Care performance and regulatory risk backdrop.
At a last close of US$187.50, DaVita’s 1-day share price return declined 3.01%, which partly offsets a 7-day share price gain of 2.10% and a 30-day share price return of 4.93%, as investors weigh stronger Q3 earnings against regulatory and legal headlines.
Compare DaVita’s mix of earnings momentum and regulatory risk with a curated set of healthcare peers screened for 34 healthcare AI stocks that could be positioned for significant policy-driven moves.
After a strong year-to-date climb and a recent pullback on fresh regulatory and legal headlines, DaVita now sits at a crossroads. Is it worth paying up after this run, or does patience on entry price matter more?
Most Popular Narrative: 15% Undervalued
DaVita’s most followed thesis pins fair value near $219.86 per share, which sits above the last close of $187.50 and puts execution in Integrated Kidney Care and cost control under the microscope.
The Integrated Kidney Care business is achieving the highest aggregate savings in its CMS program with improved quality scores and is expected to add roughly US$20 million of adjusted operating income growth in 2026 and around 1 percentage point of ongoing operating income contribution, which can support DaVita’s earnings even if U.S. dialysis reimbursement remains tight.
See why 20 investors see DaVita as 15% undervalued.
Result: Fair Value of $219.86 (UNDERVALUED)
Still, the thesis can fray if U.S. dialysis reimbursement lags cost trends for longer, or if a shift in payer mix reduces revenue per treatment more than expected.
Find out about the key risks to this DaVita narrative.
Next Steps
Mixed sentiment runs through this DaVita story, so move quickly, review the full picture, and shape your own view by weighing 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond DaVita?
If DaVita has your attention, do not stop here. Broaden your watchlist, pressure test your thesis, and give yourself better options before the next move.
- Target potential mispricings early by scanning a 33 high quality undervalued stocks that highlights companies combining quality fundamentals with compressed valuations.
- Lock in income-focused opportunities by reviewing a 5 dividend fortresses built around higher-yield payouts that still clear key balance sheet checks.
- Dial down portfolio stress by filtering for a 29 resilient stocks with low risk scores that concentrates on resilient businesses with stronger risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com